Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A from the PICASSO Trial

Background and purpose Whether pharmacologically altered high-density lipoprotein cholesterol (HDL-C) affects the risk of cardiovascular events is unknown. Recently, we have reported the Prevention of Cardiovascular Events in Asian Patients with Ischaemic Stroke at High Risk of Cerebral Haemorrhage...

Полное описание

Библиографические подробности

Главные авторы:	Eun-Jae Lee, Sun U. Kwon, Jong-Ho Park, Yong-Jae Kim, Keun-Sik Hong, Sungwook Yu, Yang-Ha Hwang, Ji Sung Lee, Juneyoung Lee, Joung-Ho Rha, Sung Hyuk Heo, Sung Hwan Ahn, Woo-Keun Seo, Jong-Moo Park, Ju-Hun Lee, Jee-Hyun Kwon, Sung-Il Sohn, Jin-Man Jung, Hahn Young Kim, Eung-Gyu Kim, Sung Hun Kim, Jae-Kwan Cha, Man-Seok Park, Hyo Suk Nam, Dong-Wha Kang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Korean Stroke Society 2020-01-01
Серии:	Journal of Stroke
Предметы:	cholesterol, hdl secondary prevention cilostazol probucol cholesterol ester transfer proteins
Online-ссылка:	http://www.j-stroke.org/upload/pdf/jos-2019-02551.pdf
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!